Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
39
TGTX Quote, Financials, Valuation and Earnings
Last price:
$31.37
Seasonality move
:
25.86%
Day range:
$30.58 - $31.79
52-week range:
$25.28 - $46.48
Dividend yield:
0%
P/E ratio:
11.38x
P/S ratio:
9.61x
P/B ratio:
8.26x
Volume:
1.5M
Avg. volume:
2M
1-year change:
-5.33%
Market cap:
$5B
Revenue:
$329M
EPS (TTM):
$2.78
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TGTX
TG Therapeutics, Inc.
|
$152M | $0.22 | 68.58% | 60.42% | $44.29 |
|
AMGN
Amgen, Inc.
|
$9B | $5.01 | 4.56% | 309.55% | $324.25 |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$87M | -$0.09 | 53.91% | -88.43% | $31.63 |
|
AXSM
Axsome Therapeutics, Inc.
|
$162.7M | -$0.90 | 57.91% | -48.97% | $181.31 |
|
KPTI
Karyopharm Therapeutics, Inc.
|
$42.4M | -$3.25 | 17.34% | -47.52% | $14.67 |
|
KRYS
Krystal Biotech, Inc.
|
$93.4M | $1.12 | 16.27% | 5.57% | $217.70 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TGTX
TG Therapeutics, Inc.
|
$31.61 | $44.29 | $5B | 11.38x | $0.00 | 0% | 9.61x |
|
AMGN
Amgen, Inc.
|
$345.42 | $324.25 | $186B | 26.70x | $2.38 | 2.76% | 5.21x |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$29.96 | $31.63 | $3.7B | -- | $0.00 | 0% | 12.03x |
|
AXSM
Axsome Therapeutics, Inc.
|
$147.81 | $181.31 | $7.5B | -- | $0.00 | 0% | 12.96x |
|
KPTI
Karyopharm Therapeutics, Inc.
|
$5.46 | $14.67 | $93.1M | -- | $0.00 | 0% | 0.33x |
|
KRYS
Krystal Biotech, Inc.
|
$217.46 | $217.70 | $6.3B | 32.62x | $0.00 | 0% | 17.39x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TGTX
TG Therapeutics, Inc.
|
29.47% | -1.933 | 4.53% | 2.53x |
|
AMGN
Amgen, Inc.
|
85.02% | 0.027 | 35.92% | 0.82x |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
41.85% | -0.694 | 5.02% | 3.07x |
|
AXSM
Axsome Therapeutics, Inc.
|
74.78% | 0.689 | 3.58% | 1.45x |
|
KPTI
Karyopharm Therapeutics, Inc.
|
-269.68% | 1.256 | 345.14% | 0.89x |
|
KRYS
Krystal Biotech, Inc.
|
0.83% | 0.141 | 0.19% | 9.43x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TGTX
TG Therapeutics, Inc.
|
$133.6M | $29.4M | 79.79% | 145.71% | 18.16% | -$23.2M |
|
AMGN
Amgen, Inc.
|
$6.5B | $2.6B | 10.74% | 95.55% | 26.65% | $4.2B |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$90.5M | $8.5M | -15.75% | -29.4% | 8.59% | -$1.8M |
|
AXSM
Axsome Therapeutics, Inc.
|
$156.7M | -$32.9M | -82.07% | -327.97% | -19.26% | $988K |
|
KPTI
Karyopharm Therapeutics, Inc.
|
$41.8M | -$15.2M | -1579.24% | -- | -34.56% | -$5.9M |
|
KRYS
Krystal Biotech, Inc.
|
$92.1M | $41.4M | 19.74% | 19.91% | 42.31% | $38M |
TG Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns TGTX or AMGN?
Amgen, Inc. has a net margin of 19.97% compared to TG Therapeutics, Inc.'s net margin of 33.55%. TG Therapeutics, Inc.'s return on equity of 145.71% beat Amgen, Inc.'s return on equity of 95.55%.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics, Inc.82.59% $2.43 $860.9M AMGNAmgen, Inc.67.85% $5.93 $64.2B -
What do Analysts Say About TGTX or AMGN?
TG Therapeutics, Inc. has a consensus price target of $44.29, signalling upside risk potential of 40.1%. On the other hand Amgen, Inc. has an analysts' consensus of $324.25 which suggests that it could fall by -6.13%. Given that TG Therapeutics, Inc. has higher upside potential than Amgen, Inc., analysts believe TG Therapeutics, Inc. is more attractive than Amgen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics, Inc.5 1 0 AMGNAmgen, Inc.10 15 2 -
Is TGTX or AMGN More Risky?
TG Therapeutics, Inc. has a beta of 2.014, which suggesting that the stock is 101.386% more volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.893%.
-
Which is a Better Dividend Stock TGTX or AMGN?
TG Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen, Inc. offers a yield of 2.76% to investors and pays a quarterly dividend of $2.38 per share. TG Therapeutics, Inc. pays -- of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or AMGN?
TG Therapeutics, Inc. quarterly revenues are $161.7M, which are smaller than Amgen, Inc. quarterly revenues of $9.6B. TG Therapeutics, Inc.'s net income of $390.9M is lower than Amgen, Inc.'s net income of $3.2B. Notably, TG Therapeutics, Inc.'s price-to-earnings ratio is 11.38x while Amgen, Inc.'s PE ratio is 26.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics, Inc. is 9.61x versus 5.21x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics, Inc.9.61x 11.38x $161.7M $390.9M AMGNAmgen, Inc.5.21x 26.70x $9.6B $3.2B
-
Which has Higher Returns TGTX or ARQT?
Arcutis Biotherapeutics, Inc. has a net margin of 19.97% compared to TG Therapeutics, Inc.'s net margin of 7.47%. TG Therapeutics, Inc.'s return on equity of 145.71% beat Arcutis Biotherapeutics, Inc.'s return on equity of -29.4%.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics, Inc.82.59% $2.43 $860.9M ARQTArcutis Biotherapeutics, Inc.91.25% $0.06 $271.8M -
What do Analysts Say About TGTX or ARQT?
TG Therapeutics, Inc. has a consensus price target of $44.29, signalling upside risk potential of 40.1%. On the other hand Arcutis Biotherapeutics, Inc. has an analysts' consensus of $31.63 which suggests that it could grow by 5.56%. Given that TG Therapeutics, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe TG Therapeutics, Inc. is more attractive than Arcutis Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics, Inc.5 1 0 ARQTArcutis Biotherapeutics, Inc.5 1 0 -
Is TGTX or ARQT More Risky?
TG Therapeutics, Inc. has a beta of 2.014, which suggesting that the stock is 101.386% more volatile than S&P 500. In comparison Arcutis Biotherapeutics, Inc. has a beta of 1.693, suggesting its more volatile than the S&P 500 by 69.345%.
-
Which is a Better Dividend Stock TGTX or ARQT?
TG Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcutis Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics, Inc. pays -- of its earnings as a dividend. Arcutis Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or ARQT?
TG Therapeutics, Inc. quarterly revenues are $161.7M, which are larger than Arcutis Biotherapeutics, Inc. quarterly revenues of $99.2M. TG Therapeutics, Inc.'s net income of $390.9M is higher than Arcutis Biotherapeutics, Inc.'s net income of $7.4M. Notably, TG Therapeutics, Inc.'s price-to-earnings ratio is 11.38x while Arcutis Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics, Inc. is 9.61x versus 12.03x for Arcutis Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics, Inc.9.61x 11.38x $161.7M $390.9M ARQTArcutis Biotherapeutics, Inc.12.03x -- $99.2M $7.4M
-
Which has Higher Returns TGTX or AXSM?
Axsome Therapeutics, Inc. has a net margin of 19.97% compared to TG Therapeutics, Inc.'s net margin of -27.62%. TG Therapeutics, Inc.'s return on equity of 145.71% beat Axsome Therapeutics, Inc.'s return on equity of -327.97%.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics, Inc.82.59% $2.43 $860.9M AXSMAxsome Therapeutics, Inc.91.62% -$0.94 $292.3M -
What do Analysts Say About TGTX or AXSM?
TG Therapeutics, Inc. has a consensus price target of $44.29, signalling upside risk potential of 40.1%. On the other hand Axsome Therapeutics, Inc. has an analysts' consensus of $181.31 which suggests that it could grow by 21.6%. Given that TG Therapeutics, Inc. has higher upside potential than Axsome Therapeutics, Inc., analysts believe TG Therapeutics, Inc. is more attractive than Axsome Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics, Inc.5 1 0 AXSMAxsome Therapeutics, Inc.16 0 0 -
Is TGTX or AXSM More Risky?
TG Therapeutics, Inc. has a beta of 2.014, which suggesting that the stock is 101.386% more volatile than S&P 500. In comparison Axsome Therapeutics, Inc. has a beta of 0.476, suggesting its less volatile than the S&P 500 by 52.416%.
-
Which is a Better Dividend Stock TGTX or AXSM?
TG Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axsome Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics, Inc. pays -- of its earnings as a dividend. Axsome Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or AXSM?
TG Therapeutics, Inc. quarterly revenues are $161.7M, which are smaller than Axsome Therapeutics, Inc. quarterly revenues of $171M. TG Therapeutics, Inc.'s net income of $390.9M is higher than Axsome Therapeutics, Inc.'s net income of -$47.2M. Notably, TG Therapeutics, Inc.'s price-to-earnings ratio is 11.38x while Axsome Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics, Inc. is 9.61x versus 12.96x for Axsome Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics, Inc.9.61x 11.38x $161.7M $390.9M AXSMAxsome Therapeutics, Inc.12.96x -- $171M -$47.2M
-
Which has Higher Returns TGTX or KPTI?
Karyopharm Therapeutics, Inc. has a net margin of 19.97% compared to TG Therapeutics, Inc.'s net margin of -75.21%. TG Therapeutics, Inc.'s return on equity of 145.71% beat Karyopharm Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics, Inc.82.59% $2.43 $860.9M KPTIKaryopharm Therapeutics, Inc.94.93% -$3.82 -$72.8M -
What do Analysts Say About TGTX or KPTI?
TG Therapeutics, Inc. has a consensus price target of $44.29, signalling upside risk potential of 40.1%. On the other hand Karyopharm Therapeutics, Inc. has an analysts' consensus of $14.67 which suggests that it could grow by 168.62%. Given that Karyopharm Therapeutics, Inc. has higher upside potential than TG Therapeutics, Inc., analysts believe Karyopharm Therapeutics, Inc. is more attractive than TG Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics, Inc.5 1 0 KPTIKaryopharm Therapeutics, Inc.3 1 0 -
Is TGTX or KPTI More Risky?
TG Therapeutics, Inc. has a beta of 2.014, which suggesting that the stock is 101.386% more volatile than S&P 500. In comparison Karyopharm Therapeutics, Inc. has a beta of 0.228, suggesting its less volatile than the S&P 500 by 77.201%.
-
Which is a Better Dividend Stock TGTX or KPTI?
TG Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Karyopharm Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics, Inc. pays -- of its earnings as a dividend. Karyopharm Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or KPTI?
TG Therapeutics, Inc. quarterly revenues are $161.7M, which are larger than Karyopharm Therapeutics, Inc. quarterly revenues of $44M. TG Therapeutics, Inc.'s net income of $390.9M is higher than Karyopharm Therapeutics, Inc.'s net income of -$33.1M. Notably, TG Therapeutics, Inc.'s price-to-earnings ratio is 11.38x while Karyopharm Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics, Inc. is 9.61x versus 0.33x for Karyopharm Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics, Inc.9.61x 11.38x $161.7M $390.9M KPTIKaryopharm Therapeutics, Inc.0.33x -- $44M -$33.1M
-
Which has Higher Returns TGTX or KRYS?
Krystal Biotech, Inc. has a net margin of 19.97% compared to TG Therapeutics, Inc.'s net margin of 81.15%. TG Therapeutics, Inc.'s return on equity of 145.71% beat Krystal Biotech, Inc.'s return on equity of 19.91%.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics, Inc.82.59% $2.43 $860.9M KRYSKrystal Biotech, Inc.94.21% $2.66 $1.1B -
What do Analysts Say About TGTX or KRYS?
TG Therapeutics, Inc. has a consensus price target of $44.29, signalling upside risk potential of 40.1%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $217.70 which suggests that it could grow by 2.55%. Given that TG Therapeutics, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe TG Therapeutics, Inc. is more attractive than Krystal Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics, Inc.5 1 0 KRYSKrystal Biotech, Inc.9 1 0 -
Is TGTX or KRYS More Risky?
TG Therapeutics, Inc. has a beta of 2.014, which suggesting that the stock is 101.386% more volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.528%.
-
Which is a Better Dividend Stock TGTX or KRYS?
TG Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or KRYS?
TG Therapeutics, Inc. quarterly revenues are $161.7M, which are larger than Krystal Biotech, Inc. quarterly revenues of $97.8M. TG Therapeutics, Inc.'s net income of $390.9M is higher than Krystal Biotech, Inc.'s net income of $79.4M. Notably, TG Therapeutics, Inc.'s price-to-earnings ratio is 11.38x while Krystal Biotech, Inc.'s PE ratio is 32.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics, Inc. is 9.61x versus 17.39x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics, Inc.9.61x 11.38x $161.7M $390.9M KRYSKrystal Biotech, Inc.17.39x 32.62x $97.8M $79.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
64
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
